OncoMatch/Clinical Trials/NCT07438847
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
Is NCT07438847 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 177Lu-CTR-FAPI therapy for thyroid cancer.
Treatment: 177Lu-CTR-FAPI therapy — This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel radiopharmaceutical in the treatment of thyroid cancer. The primary endpoint of the study is the safety of 177Lu-CTR-FAPI, and the secondary endpoints include treatment response and dosimetry evaluation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: therapeutic radionuclide therapy
Exception: 131i
Lab requirements
Blood counts
Insufficient major organ function [excluded]
Kidney function
Insufficient major organ function [excluded]
Liver function
Insufficient major organ function [excluded]
Insufficient major organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify